Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer

References

Page 1

	Year	Citations
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, CA A Cancer Journal for Clinicians	2018	86.6K
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies Martin Köbel, Steve E. Kalloger, Niki Boyd, PLoS Medicine	2008	812
Grading Ovarian Serous Carcinoma Using a Two-Tier System Anaís Malpica, Michael T. Deavers, Karen H. Lu, The American Journal of Surgical Pathology Tumoral PathologyRadiologyMitotic RateMedicineGynecology	2004	663
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary David M. Gershenson, Charlotte C. Sun, Karen H. Lu, Obstetrics and Gynecology	2006	279
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum David M. Gershenson, Diane C. Bodurka, Robert L. Coleman, Journal of Clinical Oncology Surgical OncologyGynecologyLow-grade Serous CancerCancer RegistrationSurgery	2017	256
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase Jacek Grabowski, Philipp Harter, Florian Heitz, Gynecologic Oncology MedicineCancer ManagementChemotherapy ResponsivenessGynecologyAgo Study Group	2016	219
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum David M. Gershenson, Charlotte C. Sun, Revathy B. Iyer, Gynecologic Oncology Endocrine OncologyMedicineGynecologyHormonal TherapyOncology	2012	200
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential Marta A. Crispens Obstetrics and Gynecology	2002	149
Intra‐abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer Jalid Sehouli, Filiz Senyuva, Christina Fotopoulou, Journal of Surgical Oncology	2009	129
The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study Amanda N. Fader, James Java, Thomas C. Krivak, Gynecologic Oncology MedicineCancer ManagementGrade 1GynecologyPrognostic Significance	2013	57

Page 1